OrthoPediatrics Tops Q2 Estimates and Lifts Full-Year Outlook
KIDS sits 45% above its 52-week low of $14.42.
Summary
OrthoPediatrics reported Q2 2026 revenue of $70.5M, beating estimates, and raised full-year guidance. Adjusted EBITDA nearly doubled to $6.8M, and free cash flow usage improved sharply.
Key Events · Earnings and Guidance · KIDS
-
Q2 Revenue Beat
Revenue of $70.5M exceeded the $68.25M consensus, growing 15% year-over-year driven by Trauma & Deformity (up 26%) and international sales (up 22%).
-
Adjusted EBITDA Nearly Doubled
Adjusted EBITDA reached $6.8M, up from $4.1M in Q2 2025, reflecting improved operating leverage and cost discipline.
-
Full-Year Guidance Raised
2026 revenue guidance increased to $265M-$269M from $263M-$267M, implying 12-14% growth; management reiterated expectations for cash-flow breakeven in 2026.
-
Free Cash Flow Improvement
Free cash flow usage improved 78% year-over-year to -$3.1M, driven by higher EBITDA, lower set deployments, and better working capital management.
Analysis · KIDS · Industrial Applications And Services
A clean beat underscores the quarter: revenue of $70.5M sailed past the $68.25M consensus, while adjusted EBITDA nearly doubled year-over-year to $6.8M. Management responded by raising the full-year revenue target to $265M–$269M and reaffirming its expectation for cash-flow breakeven in 2026. The results highlight a strengthening growth trajectory and improving operating leverage, with free cash flow usage shrinking 78% from the prior year. This is a strong quarter that should reinforce confidence in the pediatric orthopedics franchise.
At the time of this filing, KIDS was trading at $20.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $536.3M. The 52-week trading range was $14.42 to $22.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.